Cognitive & Mood
Semax
Semax (ACTH 4-10 fragment analog)
Russian neuroprotective peptide · ACTH 4-10 derivative
- FDA Status
- Not FDA-approved · Approved in Russia
- Class
- Heptapeptide · ACTH (4-10) Pro-Gly-Pro extension
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro
- Half-life
- ~30-60 min
Mechanism of action
- BDNF and NGF (nerve growth factor) upregulation
- Modulates dopaminergic and serotonergic systems
- Neuroprotection via anti-inflammatory pathways
- Improves cerebral blood flow
Research areas
- Acute ischemic stroke (Russian standard of care)
- Cognitive impairment and ADHD
- Optic nerve atrophy
- Memory consolidation studies
Evidence and clinical data
Approved in Russia for stroke recovery since 1990s. Western literature is sparse but growing. Phase II equivalent data exists for stroke.
Safety profile
Well-tolerated in Russian post-market data. Intranasal route minimizes systemic exposure. Limited Western pharmacovigilance.
Why this peptide is trending in 2026: Cited frequently in nootropic communities for "alertness without anxiety". Used by Russian astronauts and military reportedly.
Educational use only. PeptideAdvance does not sell Semax, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.